Extracellular Ca2+ modulates ADP-evoked aggregation through altered agonist degradation: implications for conditions used to study P2Y receptor activation by Jones, Sarah et al.
Extracellular Ca
2+ modulates ADP-evoked aggregation through
altered agonist degradation: implications for conditions used to
study P2Y receptor activation
ADP is an important platelet agonist during haemostasis and
thrombosis, exerting its effects through two G-protein-coupled
receptors P2Y1 and P2Y12 (Gachet, 2008). P2Y1 is coupled to
Gaq, leading to an increase in cytosolic calcium through
stimulation of phospholipase Cb (PLCb) (Jin et al, 1998; Savi
et al, 1998; Leon et al. 1999), whereas P2Y12 is coupled to Gai,
leading to activation of phosphatidylinositol 3-Kinase (PI3-K)
(Trumel et al, 1999; Jackson et al, 2005) and inhibition of
adenylate cyclase. For platelet-platelet adhesion, and thus
thrombus formation, activation of the ﬁbrinogen receptor
aIIbb3 is required, a process that depends upon concomitant
stimulation of Gaq and Gai signalling pathways (Jin &
Kunapuli, 1998). Several platelet agonists bind to receptors
coupled to Gaq, including thrombin, thromboxane A2 (TXA2)
and ADP. However, ADP is the only platelet agonist that
stimulates Gai signalling at physiological concentrations and is
therefore an essential co-stimulus to achieve full functional
responses for all known platelet agonists (Dorsam & Kunapuli,
2004; Gachet, 2008). Despite the central role of ADP in platelet
aggregation and thrombogenesis, it is normally considered to
be a weak platelet agonist due to the reversible nature of the
aggregation response observed in vitro at physiological levels of
external Ca
2+ (Gachet, 2008). Extremely low levels of extra-
cellular Ca
2+ abolish ﬁbrinogen binding to aIIbb3 integrin,
however at micromolar extracellular calcium concentrations,
ADP-evoked aggregation is enhanced compared to physiolog-
ical Ca
2+ levels and not readily reversible (Mustard et al, 1975;
Packham et al, 1989). Although this paradoxical effect was
reported more than two decades ago, the underlying basis
whereby extracellular calcium modulates ADP-evoked aggre-
gation remains unclear. It has been proposed that milli-
molar Ca
2+ levels inhibit TXA2 generation via altered ERK
Sarah Jones, Richard J. Evans and Martyn
P. Mahaut-Smith
Department of Cell Physiology and Pharmacology,
University of Leicester, Leicester, UK
Received 2 September 2010; accepted for
publication 1 November 2010
Correspondence: Professor Martyn P. Mahaut-
Smith, Department of Cell Physiology and
Pharmacology, University of Leicester, Maurice
Shock Medical Sciences Building, University
Road, Leicester LE1 9HN, UK.
E-mail: mpms1@leicester.ac.uk
Re-use of this article is permitted in accordance
with the Terms and Conditions set out at
http://wileyonlinelibrary.com/onlineopen#
OnlineOpen_Terms
Summary
ADP is considered a weak platelet agonist due to the limited aggregation
responses it induces in vitro at physiological concentrations of extracellular
Ca
2+ [(Ca
2+)o]. Lowering [Ca
2+]o paradoxically enhances ADP-evoked
aggregation, an effect that has been attributed to enhanced thromboxane
A2 production. This study examined the role of ectonucleotidases in the
[Ca
2+]o-dependence of platelet activation. Reducing [Ca
2+]o from millimolar
to micromolar levels converted ADP (10 lmol/l)-evoked platelet aggregation
from a transient to a sustained response in both platelet-rich plasma and
washed suspensions. Blocking thromboxane A2 production with aspirin had
no effect on this [Ca
2+]o-dependence. Prevention of ADP degradation
abolished the differences between low and physiological [Ca
2+]o resulting in a
robust and sustained aggregation in both conditions. Measurements of
extracellular ADP revealed reduced degradation in both plasma and apyrase-
containing saline at micromolar compared to millimolar [Ca
2+]o. As reported
previously, thromboxane A2 generation was enhanced at low [Ca
2+]o,
however this was independent of ectonucleotidase activity. P2Y receptor
antagonists cangrelor and MRS2179 demonstrated the necessity of P2Y12
receptors for sustained ADP-evoked aggregation, with a minor role for P2Y1.
In conclusion, Ca
2+-dependent ectonucleotidase activity is a major factor
determining the extent of platelet aggregation to ADP and must be controlled
for in studies of P2Y receptor activation.
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ary aggregation (Mustard et al, 1975; Packham et al, 1989),
however exactly how Ca
2+ achieves this effect is not known.
Following stimulation of platelet P2Y receptors with ADP,
the duration and amplitude of the response can be regulated by
two principal mechanisms, ﬁrstly, desensitization of the P2Y
receptors preventing further signalling and, secondly, removal
of ADP by ectonucleotidases. Ectonucleotidases comprise a
large family of extracellular nucleotide degrading enzymes
including ectonucleoside triphosphate diphosphohydrolases
(E-NTPDases), ectonucleotide pyrophosphatase/phosphodies-
terases (E-NPPs), alkaline phosphatases and 5¢ nucleotidase
(Zimmermann, 2000). ADP derived from platelets and other
blood cells is thought to predominantly be metabolised by
E-NTPDase1 (CD39), a membrane-bound enzyme expressed
by endothelial cells, lymphocytes and macrophages (Kansas
et al, 1991; Marcus et al, 1997), as well as microparticles that
originate from these cell types (Atkinson et al, 2006; Banz et al,
2008). CD39 converts ADP to AMP, which is subsequently
converted to adenosine, an inhibitor of platelet function, by 5¢
nucleotidase (CD73) expressed on endothelial cells and in
plasma (Coade & Pearson, 1989; Zimmermann, 2000; Hept-
install et al, 2005). There is also evidence that soluble
E-NPPases in plasma can degrade ADP directly to adenosine
(Birk et al, 2002; Cauwenberghs et al, 2006), thus ectonucle-
otidases can convert prothrombotic mediators into inhibitors
of platelet activation.
In this study we have investigated further the mecha-
nism(s) underlying the differential responses to ADP at
physiological compared to low (micromolar) extracellular
calcium concentrations. We demonstrate that degradation of
ADP by Ca
2+-dependent ectonucleotidases is an important
factor in determining the amplitude and duration of platelet
aggregation. The results have consequences for understanding
theeffectivenessofADPasaplateletagonist,andintheselection
of experimental conditions to explore P2Y receptor activation.
Materials and methods
Materials
CHRONO-LUME was purchased from Labmedics (Manches-
ter, UK), Pyruvate kinase was obtained from Roche Diagnos-
tics Limited (East Sussex, UK), GF109203X and MRS2179 were
purchased from Tocris (Bristol, UK). Thromboxane B2 (TXB2)
assay kits were purchased from Cambridge Bioscience LTD
(Cambridge, UK). Cangrelor (ARC-69931MX) was a kind gift
from AstraZeneca (Moindal, Sweden). ADP, apyrase (grade-
VII), aspirin, phosphoenolpyruvate and all other chemicals
were purchased from Sigma (Poole, UK).
Platelet preparation
Blood was obtained from healthy, aspirin-free, volunteers
according to a protocol approved by the local ethical
committee of the University of Leicester. Blood was drawn
from the forearm by venepuncture into a syringe containing
acid citrate dextrose anticoagulant (ACD: 85 mmol/l triso-
dium citrate, 78 mmol/l citric acid, 111 mmol/l glucose) 9:1 v/
v. Platelet-rich plasma (PRP) was obtained by centrifugation at
700 g for 5 min. When re-calciﬁed, 20 mmol/l CaCl2 [calcu-
lated using a Nomogram (Hastings et al, 1934)] was added to
citrated PRP to achieve [Ca
2+]o of approximately 2 mmol/l
immediately prior to each experiment. The extracellular Ca
2+
in nominally Ca
2+-free saline and in similar citrated plasma:
saline mixtures has been estimated to be approximately 20 and
17 lmol/l respectively (Packham et al, 1987; Rolf et al, 2001).
To prepare washed platelet suspensions, apyrase (0Æ32 u/ml)
and, where stated, aspirin (100 lmol/l or 1 mmol/l) were
added to the PRP and platelets pelleted by centrifugation at
350 g for 20 min. Platelets were then resuspended in a volume
of nominally Ca
2+-free saline (145 mmol/l NaCl, 5 mmol/l
KCl, 1 mmol/l MgCl2 10 mmol/l HEPES, 10 mmol/l glucose,
1 g/l ﬁbrinogen pH 7Æ35) equal to that of the removed plasma,
with or without apyrase (0Æ32 u/ml) as required by the speciﬁc
experiment. In experiments performed at physiological cal-
cium concentrations, 2 mmol/l CaCl2 was added to the
platelets immediately prior to use.
Platelet aggregation
PRP or washed platelet suspensions were diluted (1:1) in saline
with or without apyrase (0Æ32 u/ml) and stimulated with ADP
at 37 C under stirring conditions. Aggregation was measured
using optical aggregometry (Model 400 lumi-aggregometer;
Chronolog, Havertown, PA, USA).
Platelet disaggregation
Washed, apyrase-free platelets were stimulated with ADP
(10 lmol/l) at 37 C under stirring conditions in the presence
of 2 mmol/l Ca
2+. After 2 min, apyrase (0Æ32 u/ml), the P2Y1
receptor antagonist MRS2179 (10 lmol/l), the P2Y12 receptor
antagonist AR-C69931MX (1 lmol/l) or a saline control was
added to the suspension. Disaggregation was assessed 3 min
after the addition of the P2Y receptor antagonists or apyrase
and calculated as a percentage of the peak ADP-evoked
aggregation.
ADP measurement
The concentration of extracellular ADP was assessed by
luciferin:luciferase luminescence measurements after conver-
sion to ATP via a method adapted from Heath (2004). Brieﬂy,
2 min after addition of 10 lmol/l ADP to plasma or apyrase-
containing saline, with or without Ca
2+,5 0ll samples were
removed and added to a mixture of 420 ll Tris-K acetate
buffer (100 mmol/l Tris-acetate, 2 mmol/l EDTA, 25 mmol/l
potassium acetate), 10 ll pyruvate kinase/phosphoenol-
pyruvate (prepared by mixing equal volumes of 10 mg/ml
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20 ll CHRONO-LUME. Luminescence was measured using a
Model 400 lumi-aggregometer (Chronolog) and converted to
ATP levels based upon a calibration curve for each batch of
CHRONO-LUME.
TXB2 measurements
TXB2 synthesis was measured as an indication of TXA2
production due to the highly labile nature of TXA2. Washed
platelets were stimulated with ADP (10 lmol/l) at 37 C under
stirring conditions for 3 min in the presence and absence of
apyrase (0Æ32 u/ml), in both physiological Ca
2+ and nominally
Ca
2+-free conditions, and reactions terminated by snap
freezing. For analysis of TXB2, samples were thawed and
centrifuged at 3000 g for 10 min at 4 C. The supernatant was
diluted 1:5 using the buffer supplied with the assay kit and
TXB2 determined according to the manufacturer’s instructions
(Cambridge Bioscience).
Statistics
Records of aggregation are from individual experiments,
typical of 3–7 donors. Differences between means ± SEM were
assessed using paired Student’s t-test and a P value of <0Æ05
was considered to be signiﬁcant. P values are indicated at levels
of <0Æ05 (*), <0Æ01 (**) and <0Æ001 (***).
Results
Extracellular Ca
2+ levels regulate ADP-evoked aggregation
independently of TXA2 synthesis
ADP (10 lmol/l) evoked a sustained aggregation of platelets in
plasma anti-coagulated with citrate that reduced the extra-
cellular Ca
2+ concentration [(Ca
2+)o] to the micromolar range
(Fig 1A, E; average peak aggregation of 53Æ9±3 Æ4%). When
the medium was recalciﬁed to approximately 2 mmol/l free
Ca
2+, the aggregation was converted to a transient response
that returned to baseline levels of transmission ()2Æ8 ± 2%)
within approximately 2 min (Fig 1A, E). Previous studies of
this [Ca
2+]o-dependent aggregation response showed that
production of TXA2 was enhanced at micromolar compared
to millimolar [Ca
2+]o levels and concluded that secondary
stimulation of TXA2 receptors is responsible for the reversible
nature of the ADP-evoked aggregation (Mustard et al, 1975;
Packham et al, 1989; Garcia et al, 2007). However, we
observed a similar effect of [Ca
2+]o on aggregation when
TXA2 synthesis was blocked by aspirin (Fig 1B, E; average
values at 2 min of 50Æ7 ± 3% and 0Æ9±0 Æ3% in low and
physiological Ca
2+ levels respectively). In platelets resuspended
in a physiological saline with apyrase, 10 lmol/l ADP evoked a
transient aggregation response in the presence of 2 mmol/l
[Ca
2+]o, which was also converted to a sustained response by
omission of CaCl2 from the saline (Fig 1C, E; transmission
levels 2 min after ADP of 0Æ6 ± 2% and 53Æ2±5 Æ4%, respec-
tively), in agreement with reports by other groups (Mustard
et al, 1975; Packham et al, 1989). As observed for platelets in
the presence of plasma, aspirin did not block the sustained
aggregation in salines with micromolar [Ca
2+]o (Fig 1D, E;
average values at 2 min of 55Æ9±1 Æ3% and 7Æ1±4 Æ2% in low
and physiological Ca
2+ levels respectively). To ensure that
TXA2 generation was completely inhibited, experiments were
repeated in the presence of 1 mmol/l aspirin, which also had
no signiﬁcant effect on the ability of reduced [Ca
2+]o to
enhance platelet aggregation (P >0 Æ05, data not shown).
Together, these data suggest that factor(s) other than altered
TXA2 production must contribute to the ability of reduced
[Ca
2+]o to enhance ADP-evoked aggregation.
Prevention of ADP degradation abolishes the reversal of
aggregation by calcium
Given that our washed platelet preparation contained apyrase
(E-NTPDase1 isolated from potato to prevent P2Y receptor
desensitization) and PRP has been reported to contain
endogenous ectonucleotidases, we considered whether degra-
dation of ADP contributed to the transient nature of the ADP-
evoked aggregation at millimolar Ca
2+ levels. Aggregation
evoked by the hydrolysis-resistant analogue ADPbS was not
signiﬁcantly different in the presence or absence of extracel-
lular Ca
2+ (Fig 2A, D; aggregation at 2 min of 45Æ8±3 Æ7% and
42Æ9±5 Æ6% in normal and low [Ca
2+]o, respectively;
P >0 Æ05). Moreover, when platelets were resuspended in the
absence of apyrase, and experiments performed rapidly to limit
the effects of desensitization, ADP-evoked aggregation was also
sustained in the presence of 2 mmol/l extracellular Ca
2+
(Fig 2B, D; 59Æ3±3 Æ8 and 61Æ9±2 Æ4% in normal and low
Ca
2+ respectively). Finally, the [Ca
2+]o-dependence of ADP-
evoked aggregation responses in plasma was abolished when
platelets were resuspended in autologous heat-treated plasma
(60 C, 30 min) to destroy enzymatic activity (Fig 2C, D;
41Æ1±1 Æ1 and 41Æ5±1 Æ9% in millimolar versus micromolar
[Ca
2+]o respectively). Together, these observations are consis-
tent with a role for Ca
2+-dependent nucleotidase activity in the
[Ca
2+]o-dependence to ADP-evoked sustained aggregation
responses.
ADP degradation is accelerated by millimolar calcium
concentrations
To directly assess the extent of ADP degradation in millimolar
versus micromolar [Ca
2+]o concentrations, ADP (10 lmol/l)
was added to apyrase-treated saline or platelet-free plasma and
the ADP concentration after 2 min measured by luminescence
following conversion to ATP (see Methods). The concentration
of ADP remaining in nominally Ca
2+-free saline was
1Æ61 ± 0Æ06 lmol/l, which was signiﬁcantly reduced to 0Æ079
±0 Æ03 lmol/l (P <0 Æ001) in the presence of 2 mmol/l Ca
2+,
indicating accelerated nucleotidase activity by physiological
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2+]o (Fig 3A). Similarly, ADP incubated with citrated
plasma was degraded, from 10 to 2Æ1±0 Æ27 lmol/l, by
enzymes endogenous to plasma, whereas under recalciﬁed
conditions the ADP remaining was markedly lower, at
0Æ78 ± 0Æ14 lmol/l (P <0 Æ001) (Fig 3B). A signiﬁcant effect
of [Ca
2+]o on degradation of 10 lmol/l ADP was also detected
at earlier time points, as shown by measurements after only
10 s (Figure S1). This suggests that platelets in the presence of
millimolar Ca
2+ are exposed to a reduced level of ADP
throughout most of the experiment compared to at micro-
molar Ca
2+ levels. In contrast, addition of 2 mmol/l MgCl2 to
nominally Ca
2+-free saline did not signiﬁcantly affect ADP
degradation or lead to a transient aggregation response
(Figure S2). Together with the data in Fig 2, these results
support the conclusion that reduced ADP degradation
substantially contributes to the paradoxical amplifying effect
of reducing Ca
2+ on platelet aggregation. This is also consistent
with the reported enhancement of ectonucleotidase activity at
millimolar concentrations of calcium compared to its nominal
absence or in the presence of a chelator, such as EGTA
(Christoforidis et al, 1995; Strobel et al, 1996; Marcus et al,
1997).
Reversal of aggregation is due to removal of ADP, not
negative feedback by adenosine
In plasma, 5¢ nucleotidases convert AMP generated by the
degradation of ATP and ADP to adenosine (Coade & Pearson,
1989; Heptinstall et al, 2005), thus we also considered whether
the transient responses to ADP in plasma involved inhibition
via Gas-coupled adenosine A2a receptors. In citrated PRP,
adenosine (10 lmol/l) inhibited ADP (10 lmol/l)-evoked
responses, resulting in aggregation responses similar to those
observed with ADP in physiological calcium concentrations
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Fig 1. Platelet responses to ADP are sustained at low extracellular calcium concentrations. Sample (A–D) or average (E) responses to 10 lmol/l ADP
without added extracellular Ca
2+ (low Ca
2+) or in the presence of approximately 2 mmol/l external Ca
2+. (A) citrated PRP; (B) citrated PRP treated
with aspirin (100 lmol/l); (C) platelets resuspended in saline containing apyrase (0Æ32 u/ml); (D) platelets resuspended in saline containing apyrase
(0Æ32 u/ml) and aspirin (100 lmol/l); (E) Aggregation measured at 2 min.
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addition of adenosine deaminase (1 u/ml). In recalciﬁed PRP,
the addition of adenosine deaminase had no effect on ADP-
evoked aggregation (Fig 4), indicating that negative feedback
by the generation of adenosine does not contribute to the
reversibility of ADP-mediated responses.
Sustained aggregation to ADP requires constant P2Y12
receptor stimulation
We next sought to determine whether reversal of aggregation
by Ca
2+-dependent nucleotidases was due to loss of activation
of P2Y1, P2Y12 or both receptors. Disaggregation of ADP
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apyrase (0Æ32 u/ml), the P2Y12 antagonist cangrelor (1 lmol/l)
or the P2Y1 antagonist MRS2179 (10 lmol/l) (Fig 5A).
Cangrelor reversed aggregation by 74Æ6±5 Æ9%, comparable
to that observed with apyrase 74Æ9±1 Æ2% (Fig 5B). In
contrast, MRS2179 caused a more moderate reversal of
aggregation (reduction of 24Æ0±7 Æ8%; Fig 5B). Thus, reversal
of ADP-induced aggregation by ectonucleotidases is largely
due to loss of signalling through P2Y12 receptors.
TXA2 generation is enhanced at low extracellular calcium
concentrations independently of altered ectonucleotidase
activity
To investigate whether the reduced TXA2 generation previously
reported by others (Harfenist et al, 1987; Packham et al, 1987,
1989)atmillimolar[Ca
2+]owasaconsequenceofterminationof
ADP signalling by ectonucleotidases, the effect of apyrase
(0Æ32 u/ml) at micromolar and millimolar [Ca
2+]o was exam-
ined on TXB2 production from washed platelets 3 min after
stimulationwith10 lmol/lADP(Fig 6).Asreportedpreviously
(Harfenist et al, 1987; Packham et al, 1987, 1989), TXB2
productionfromapyrase-treatedplateletswasmarkedlyreduced
at physiological extracellular Ca
2+ concentrations compared to
that observed in the nominal absence of Ca
2+. However, similar
results were observed in saline lacking apyrase. This indicates
that although increased [Ca
2+]o reduces TXB2 synthesis, this is
not dependent on the effect of Ca
2+ on ectonucleotidases.
Relative contribution of ADP degradation versus P2Y
receptor desensitization in limiting platelet responses to
ADP
P2Y1 and P2Y12 receptors are both susceptible to receptor
desensitization after prolonged agonist stimulation (Hardy
et al, 2005; Mundell et al, 2006). To determine the relative
importance of receptor desensitization versus ectonucleotidase
activity in ADP-evoked aggregation, the pan-PKC inhibitor
GF109203X was used to attenuate receptor desensitization and
aggregation was measured in citrated PRP before and after
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ADP (2 lmol/l) was used for these experiments to unmask a
clear potentiating effect of PKC inhibition, which increased
the sustained aggregation at 3 min from 36Æ9±6 Æ5% to
60Æ5±5 Æ6% in micromolar [Ca
2+]o (Fig 7B). In contrast, after
recalciﬁcation, aggregation in the presence of GF109203X or
vehicle control, was not signiﬁcantly different and returned to
baseline levels of )3Æ5±1 Æ6% and 2Æ7±1 Æ2% (P >0 Æ05),
respectively, 3 min after stimulation (Fig 7B). Thus, ADP
degradation overrides any contribution by P2Y receptor
desensitization to the reversal of aggregation in physiological
external Ca
2+ concentrations.
Discussion
Reports of differential platelet responses to ADP in physio-
logical versus nominally Ca
2+-free conditions emerged over
20 years ago (Mustard et al, 1975; Packham et al, 1989).
These studies concluded that enhanced TXA2 production
accounts for the paradoxical amplifying effect of lowering
Ca
2+ on ADP-evoked aggregation. The present study now
shows that altered degradation of ADP can also contribute to
this phenomenon. The known Ca
2+-dependence of ecto-
ADPases (Marcus et al, 1997; Zimmermann, 2000) provides
the basis for the difference observed in millimolar versus
micromolar [Ca
2+]o and this conclusion is supported by
direct measurements of ADP. The sustained aggregation
evoked by ADP is largely due to stimulation of P2Y12
receptors, consistent with previous reports of the more
crucial role of this Gi-coupled pathway compared to P2Y1 in
amplifying responses to ADP, collagen and thrombin recep-
tors (Trumel et al, 1999; Dorsam & Kunapuli, 2004; Hechler
et al, 2005; Jackson et al, 2005; Cosemans et al, 2006). The
present results also highlight the importance of controlling
for nucleotide breakdown in studies of P2 receptor signalling
when the external Ca
2+ concentration is modiﬁed. For
example, it is common practice to include soluble apyrase
to limit P2 receptor desensitization within in vitro experi-
ments and simply to vary the external [Ca
2+] to investigate
the relative contribution of Ca
2+ entry versus release pathways
in nucleotide-evoked signalling events.
The limited aggregation response at normal [Ca
2+]o has
contributed to the view that ADP is a ‘weak platelet agonist’.
However, when metabolism of ADP is limited, the ability of
this agonist to stimulate sustained aggregation, as shown in the
present study, is more consistent with the substantial reduction
in platelet activation observed in P2Y1 and P2Y12 receptor-
deﬁcient mice (Fabre et al, 1999; Leon et al, 1999; Andre et al,
2003) and the major role of ADP in amplifying collagen- and
thrombin-evoked responses in vitro. It is possible that dense
granule secretion evoked by collagen and thrombin provides a
more sustained source of ADP compared to the single bolus
application used in standard in vitro experiments. Further-
more, ATP (and thus also ADP) remains sustained for a
considerable time near sites of vascular injury (Born & Kratzer,
1984), probably reﬂecting the continual recruitment and
activation of platelets during the haemostatic process. Thus,
the in vitro experimental condition that limits ADP degrada-
tion, such as micromolar [Ca
2+]o, may more closely represent
the ability of this agonist to stimulate platelet function in vivo.
Alternatively, use of a non-hydrolysable analogue, such as
ADPbS, or repeated application of ADP to replace degraded
agonist should be considered within in vitro studies designed
to investigate mechanisms of ADP-dependent platelet activa-
tion.
Whilst ADP degradation signiﬁcantly contributed to the
transient nature of the responses to ADP in millimolar [Ca
2+]o,
we agree with earlier studies (Packham et al, 1989; Garcia et al,
2007) that TXA2 generation is lower at millimolar compared to
micromolar [Ca
2+]o. In our experiments, the marked enhance-
ment of TXB2 generation by lowering [Ca
2+]o was also
observed in apyrase-free saline, indicating that the Ca
2+-
dependent modulation of TXA2 generation can occur inde-
pendently of effects on ectonucleotidase activity. It has been
reported that reduced TXA2 synthesis in physiological calcium
concentrations is the result of inhibited ERK phosphorylation
(Garcia et al, 2007), however the process by which this is
achieved is unclear, and whether these effects are downstream
of an extracellular event or whether calcium inﬂux is required,
remains to be investigated. In the present study, 10 lmol/l
ADP stimulated sustained aggregation at millimolar [Ca
2+]o in
the absence of apyrase, conditions under which there was no
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Fig 7. ADP degradation is the predominant mechanism regulating ADP-mediated platelet aggregation at physiological extracellular Ca
2+ concen-
trations. (A) Platelet aggregation evoked by 2 lmol/l ADP in PRP before and after re-calciﬁcation, in the presence and absence of the PKC inhibitor
GF 109203X (10 lmol/l). (B) Average aggregation 3 min after addition of ADP.
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independent of secondary signalling through TXA2 receptors.
At lower concentrations of ADP, however, the release of
secondary agonists is required to achieve full aggregation,
therefore the effect of extracellular calcium on TXA2 produc-
tion may be more signiﬁcant, and modulation of ADP-evoked
aggregation by [Ca
2+]o may result from a combination of both
altered ectonucleotidase activity and TXA2 production.
Although we did not observe any difference in aggregation
within the normal physiological range of extracellular calcium
concentrations (0Æ5–2 mmol/l) (three donors, data not
shown), results from this study demonstrate the impact of
variable ectonucleotidase activity on platelet function, which
may have profound implications in certain clinical conditions.
It has previously been reported that in blood from patients
with elevated leucocyte counts, degradation of ADP is
accelerated and aggregation in response to ADP is reduced
due to increased NTPDase levels (Pulte et al, 2007; Glenn et al,
2008). Moreover, in a rat model of cholestatic liver disease
where plasma ectonucleotidase activity is enhanced, reduced
aggregation was exhibited in response to ADP and low dose
collagen (which is dependent on ADP secretion) (Witters et al,
2010). Conversely, individuals demonstrating reduced ectonu-
cleotidase expression may have more reactive platelets and be
more susceptible to thrombotic events. Such patients may
beneﬁt from therapeutic intervention with soluble forms of
NTPDase1.
In conclusion, the present study shows that reduced
degradation of ADP by ectonucleotidases contributes to the
paradoxical ampliﬁcation of ADP-evoked aggregation at
micromolar compared to millimolar extracellular Ca
2+ levels.
The sustained inside-out activation of ﬁbrinogen receptors
that occurs in response to ADP at low [Ca
2+]o is likely to be
more representative of the potential contribution of ADP to a
developing thrombus in vivo, where a constant supply of this
P2Y receptor agonist from activated platelets can override
enzymatic clearance in the vicinity of a developing thrombus.
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